← Leaderboards
Thomas A Campbell
University Of Colorado Denver
$2,616,890
Attributed
$2,616,890
Total exposure
50
Grants
38
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $781K · FY2005–08$1M$750K$500K$250K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$2,616,890 · 50
By mechanism
M01$2,616,890 · 50
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- John K Hewitt$34,018,905
- Catherine Stevens-Simon$615,282
- Thomas J Crowley$10,535,347
- Stanley J Szefler$16,550,328
- Christina M Mitchell$3,338,731
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelFundingResourcesGrantInstitutionUnited States National Institutes Of HealthSourceComputer Retrieval Of Information On Scientific Projects DatabasePharmaceutical PreparationsPurposeBloodHiv InfectionsSafetyRandomizedProtocols, TreatmentAids Clinical Trial GroupRitonavirProtease InhibitorAnti-Hiv AgentsHiv-1Cd4 Lymphocyte CountCellsLamivudineEnrollment
Grant awards (55)
ACTG A5202 (VS 10): TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RITONAVIR$56,081
M01 · FY2008 · RR · contact PI
ACTG A5001 - LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL$42,183
M01 · FY2008 · RR · contact PI
EVALOF EFFICACY OF ONCE/DAY PROTEASE INHBTR& ONCE/DAY NONNUCLEOSIDE REVERSE$19,262
M01 · FY2008 · RR · contact PI
SUPPRESSIVE LONG-TERM ANTIVIRAL MGMT OF HCV & HIV-1 COINFECTED SUBJECTS (SLAM-C)$14,142
M01 · FY2008 · RR · contact PI
ACTG A5164(V 20)-ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS W/ACUTE OIS$9,021
M01 · FY2008 · RR · contact PI
ACTG 362-METAB,CARDIOVAS&NEUROLCOMPLICA'S IN SUBJ'S W/PAST CD4 CELL$4,389
M01 · FY2008 · RR · contact PI
CEREBRAL & NEUROCOGNITIVE FNCTN IN HIV-INFECTED PRSNS W/ADVNCD HRT DISZ ON HAART$4,145
M01 · FY2008 · RR · contact PI
ACTG A5211-SAFETY AND EFFICACY OF SCH 417690 IN HIV-INF, TRTMNT-EXP SUBJCTS$2,682
M01 · FY2008 · RR · contact PI
MEASURE CLEARANCE OF REPLICATION-COMPETENT HIV-1 IN RESTING MEMORY CD4+ CELLS$975
M01 · FY2008 · RR · contact PI
ACTG A5095 -PROTEASE INHIBITOR-SPARING REGIMENS FOR THE INITIAL TREATMENT OF HIV$731
M01 · FY2008 · RR · contact PI
ACTG A5030-VALGANCICLOVIR PRE-EMPTIVE THERAPY FOR CYTOMEGALOVIRUS (CMV) VIREMIA$487
M01 · FY2008 · RR · contact PI
ACTG A5146:IMPACT OF THERAPEUTIC DRUG MONITORING (TDM) ON VIROLOGIC RESPONSE$244
M01 · FY2008 · RR · contact PI
ACTG A5202 (VS 10): TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RITONAVIR$284,234
M01 · FY2007 · RR · contact PI
ACTG A5001 - LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL$213,793
M01 · FY2007 · RR · contact PI
EVALOF EFFICACY OF ONCE/DAY PROTEASE INHBTR& ONCE/DAY NONNUCLEOSIDE REVERSE$97,626
M01 · FY2007 · RR · contact PI
SUPPRESSIVE LONG-TERM ANTIVIRAL MGMT OF HCV & HIV-1 COINFECTED SUBJECTS (SLAM-C)$71,675
M01 · FY2007 · RR · contact PI
ACTG A5164(V 20)-ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS W/ACUTE OIS$45,723
M01 · FY2007 · RR · contact PI
ACTG 362-METAB,CARDIOVAS&NEUROLCOMPLICA'S IN SUBJ'S W/PAST CD4 CELL$22,244
M01 · FY2007 · RR · contact PI
CEREBRAL & NEUROCOGNITIVE FNCTN IN HIV-INFECTED PRSNS W/ADVNCD HRT DISZ ON HAART$21,010
M01 · FY2007 · RR · contact PI
ACTG A5211-SAFETY AND EFFICACY OF SCH 417690 IN HIV-INF, TRTMNT-EXP SUBJCTS$13,595
M01 · FY2007 · RR · contact PI
MEASURE CLEARANCE OF REPLICATION-COMPETENT HIV-1 IN RESTING MEMORY CD4+ CELLS$4,942
M01 · FY2007 · RR · contact PI
ACTG A5095 -PROTEASE INHIBITOR-SPARING REGIMENS FOR THE INITIAL TREATMENT OF HIV$3,707
M01 · FY2007 · RR · contact PI
ACTG A5030-VALGANCICLOVIR PRE-EMPTIVE THERAPY FOR CYTOMEGALOVIRUS (CMV) VIREMIA$1,237
M01 · FY2007 · RR · contact PI
ACTG A5146:IMPACT OF THERAPEUTIC DRUG MONITORING (TDM) ON VIROLOGIC RESPONSE$1,235
M01 · FY2007 · RR · contact PI
ACTG A5001 - LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL$146,242
M01 · FY2006 · RR · contact PI
ACTG A5211-SAFETY AND EFFICACY OF SCH 417690 IN HIV-INF, TRTMNT-EXP SUBJCTS$95,972
M01 · FY2006 · RR · contact PI
EVALOF EFFICACY OF ONCE/DAY PROTEASE INHBTR& ONCE/DAY NONNUCLEOSIDE REVERSE$81,348
M01 · FY2006 · RR · contact PI
ACTG A5202 (VS 10): TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RITONAVIR$65,809
M01 · FY2006 · RR · contact PI
ACTG A5142-COMPARE LPV/RTV+EFV VSLPV/RTV+D4T(AZT)+3TC VSEFV+D4T EXTRLS+3TC$58,496
M01 · FY2006 · RR · contact PI
ACTG A5146:IMPACT OF THERAPEUTIC DRUG MONITORING (TDM) ON VIROLOGIC RESPONSE$45,702
M01 · FY2006 · RR · contact PI
ACTG A5030-VALGANCICLOVIR PRE-EMPTIVE THERAPY FOR CYTOMEGALOVIRUS (CMV) VIREMIA$34,734
M01 · FY2006 · RR · contact PI
ACTG 362-METAB,CARDIOVAS&NEUROLCOMPLICA'S IN SUBJ'S W/PAST CD4 CELL$31,076
M01 · FY2006 · RR · contact PI
SUPPRESSIVE LONG-TERM ANTIVIRAL MGMT OF HCV & HIV-1 COINFECTED SUBJECTS (SLAM-C)$24,678
M01 · FY2006 · RR · contact PI
ACTG A5164(V 20)-ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS W/ACUTE OIS$17,365
M01 · FY2006 · RR · contact PI
ACTG A5073 COMPARE ANTIRETROVIRAL THERAPY & SELF-ADMINISTERED & OBSERVED THERAPY$15,539
M01 · FY2006 · RR · contact PI
MEASURE CLEARANCE OF REPLICATION-COMPETENT HIV-1 IN RESTING MEMORY CD4+ CELLS$10,968
M01 · FY2006 · RR · contact PI
DOSE-FINDING SAFETY & ACTIVITY STUDY OF AMD11070 IN HIV-INFECTED SUBJECTS$5,484
M01 · FY2006 · RR · contact PI
ACTG A5095 -PROTEASE INHIBITOR-SPARING REGIMENS FOR THE INITIAL TREATMENT OF HIV$2,745
M01 · FY2006 · RR · contact PI
ACTG A5095 -PROTEASE INHIBITOR-SPARING REGIMENS FOR THE INITIAL TREATMENT OF HIV$176,942
M01 · FY2005 · RR
ACTG A5073 COMPARE ANTIRETROVIRAL THERAPY &SELF-ADMINISTERED &OBSERVED THERAPY$147,451
M01 · FY2005 · RR
ACTG A5142-COMPARE LPV/RTV+EFV VSLPV/RTV+D4T(AZT)+3TC VSEFV+D4T EXTRLS+3TC$75,568
M01 · FY2005 · RR
ACTG A5118 COMBTHERAPY W/2ND-GEN AGNTS FOR HIV PTS FAILING CURRENT THERAPY$30,412
M01 · FY2005 · RR
SUPPRESSIVE LONG-TERM ANTIVIRAL MGMT OF HCV &HIV-1 COINFECTED SUBJECTS (SLAM-C)$26,727
M01 · FY2005 · RR
ACTG A5146:IMPACT OF THERAPEUTIC DRUG MONITORING (TDM) ON VIROLOGIC RESPONSE$19,353
M01 · FY2005 · RR
MEASURE CLEARANCE OF REPLICATION-COMPETENT HIV-1 IN RESTING MEMORY CD4+ CELLS$17,509
M01 · FY2005 · RR
ACTG A5116:2 REGIMEN TRIAL FOR HIV SUBJECTS FROM ACTG 388 HAVING <200 HIV-1 RNA$14,744
M01 · FY2005 · RR
ACTG A5164(V 20)-ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS W/ACUTE OIS$9,215
M01 · FY2005 · RR
ACTG A5115:STUDY ANTIRETROVIRAL SWITCH@LOWER VS HIGHER HIV-1 RNA LEVELS$5,529
M01 · FY2005 · RR
ACTG A5211-SAFETY AND EFFICACY OF SCH 417690 IN HIV-INF, TRTMNT-EXP SUBJCTS$3,685
M01 · FY2005 · RR
DOSE-FINDING SAFETY &ACTIVITY STUDY OF AMD11070 IN HIV-INFECTED SUBJECTS$2,765
M01 · FY2005 · RR
ACTG A5073 Compare Antiretroviral Therapy$160,413
M01 · FY2004 · RR
ACTG A5095 -PROTEASE INHIBITOR-SPARING REGIMENS$151,687
M01 · FY2004 · RR
ACTG A5118 Combination Tx w/2nd-Gen. Agents for HIV$112,088
M01 · FY2004 · RR
ACTG A5142-Compare LPV/RTV+EFV vs. LPV/RTV+d4T(AZT)+3TC$86,583
M01 · FY2004 · RR
ACTG A5115:Study Antiretroviral Switch;HIV-1 RNA Levels$4,698
M01 · FY2004 · RR